表紙
市場調査レポート

腹部肥満症:パイプライン分析

Abdominal Obesity - Pipeline Review, H1 2015

発行 Global Markets Direct 商品コード 283202
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
腹部肥満症:パイプライン分析 Abdominal Obesity - Pipeline Review, H1 2015
出版日: 2015年06月30日 ページ情報: 英文 55 Pages
概要

腹部肥満症は、お腹回りの脂肪、臨床的には中心性肥満としても知られ、胃と腹部周辺に過剰な腹部脂肪がついた状態を指します。その本当の原因は未だに分かっていませんが、遺伝子と環境との間に何か結びつきがあるとされています。原因として、インスリン感受性の低下、母親の喫煙、エストロゲン性食物の摂取、遺伝、深夜の飲食習慣、ストレス、緊張、胃腸障害、消化不良等が挙げれらます。

当レポートでは、腹部肥満症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

腹部肥満症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Aileron Therapeutics, Inc.
  • Genfit SA
  • Neothetics, Inc.
  • Zafgen Inc.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (salmeterol xinafoate + fluticasone propionate)
  • ALRN-5281
  • elafibranor
  • salmeterol xinafoate
  • ZGN-839

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6789IDB

Summary

Global Markets Direct's, 'Abdominal obesity - Pipeline Review, H1 2015', provides an overview of the Abdominal obesity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Abdominal obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Abdominal obesity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Abdominal obesity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Abdominal obesity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Abdominal obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Abdominal obesity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Abdominal obesity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Abdominal obesity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Abdominal Obesity Overview
  • Therapeutics Development
    • Pipeline Products for Abdominal Obesity - Overview
    • Pipeline Products for Abdominal Obesity - Comparative Analysis
  • Abdominal Obesity - Therapeutics under Development by Companies
  • Abdominal Obesity - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Abdominal Obesity - Products under Development by Companies
  • Abdominal Obesity - Companies Involved in Therapeutics Development
    • Aileron Therapeutics, Inc.
    • Genfit SA
    • Neothetics, Inc.
    • Zafgen Inc.
  • Abdominal Obesity - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (salmeterol xinafoate + fluticasone propionate) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALRN-5281 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • elafibranor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • salmeterol xinafoate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZGN-839 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Abdominal Obesity - Recent Pipeline Updates
  • Abdominal Obesity - Dormant Projects
  • Abdominal Obesity - Discontinued Products
  • Abdominal Obesity - Product Development Milestones
    • Featured News & Press Releases
      • Apr 13, 2015: Neothetics Initiates Pivotal Phase 3 Clinical Trials for LIPO-202, the First Non-Invasive Injectable Drug Candidate for Reduction of Subcutaneous Abdominal Fat
      • Mar 23, 2015: Neothetics Initiates Study to Evaluate Safety of Retreatment With LIPO-202 for Body Contouring
      • Feb 12, 2015: Leading Aesthetic Physicians Join Neothetics' Newly Formed Corporate Advisory Board
      • Sep 30, 2013: Lithera Reports Positive Clinical Study Results From Its Phase 2b RESET Trial for LIPO-202, a Novel Treatment for Abdominal Body Contouring
      • May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial
      • Apr 02, 2013: Lithera Receives Patent From USPTO Protecting Methods Of Use And Formulations For LIPO-202
      • Mar 12, 2013: Lithera Initiates Phase IIb Clinical Trial Of LIPO-202 Targeting Aesthetic Reduction Of Subcutaneous Abdominal Fat
      • Feb 26, 2013: Aileron Therapeutics To Highlight Stapled Peptide Pipeline At 2013 AsiaTIDES Meeting
      • Sep 06, 2012: Aileron Therapeutics Unveils New Therapeutic Drug Program; Appoints Hubert C Chen As Vice President of Clinical Development
      • Sep 06, 2011: GENFIT Publishes GFT505 Clinical Trial Results In Diabetes Care
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Abdominal Obesity, H1 2015
  • Number of Products under Development for Abdominal Obesity - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Abdominal Obesity - Pipeline by Aileron Therapeutics, Inc., H1 2015
  • Abdominal Obesity - Pipeline by Genfit SA, H1 2015
  • Abdominal Obesity - Pipeline by Neothetics, Inc. , H1 2015
  • Abdominal Obesity - Pipeline by Zafgen Inc., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Assessment by Combination Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Abdominal Obesity Therapeutics - Recent Pipeline Updates, H1 2015
  • Abdominal Obesity - Dormant Projects, H1 2015
  • Abdominal Obesity - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Abdominal Obesity, H1 2015
  • Number of Products under Development for Abdominal Obesity - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top